Preventive cardiologyEfficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins
Section snippets
Methods
This randomized, double-blinded, double-dummy, parallel-group, multicenter study evaluating the efficacy and tolerability of fluvastatin XL 80 mg/day and ezetimibe 10 mg/day, alone or in combination, was conducted according to the ethical principles of the Guidelines for Good Clinical Practice and the Declaration of Helsinki of the World Medical Association. Patients were recruited in 27 centers in Germany, Greece, Norway, Russia, Turkey, and the United States from May to September 2005. Local
Results
In total 251 subjects were screened and 218 patients were randomized to treatment (Figure 1). An audit by the sponsor of 1 study center detected significant irregularities related to another study; however, there were no such findings related to this trial. As a precautionary measure, patients recruited at this center (n = 19) were excluded from the final analyses, leaving 199 patients in the intent-to-treat/safety population. Inclusion or exclusion of these 19 patients did not affect the
Discussion
The present trial demonstrates that most patients who are intolerant to other statins, due to muscular complaints without creatine kinase increases, can tolerate fluvastatin XL 80 mg/day as monotherapy or in combination with ezetimibe 10 mg/day. Fluvastatin XL 80 mg/day administered in combination with ezetimibe 10 mg/day provides substantial additional lowering of LDL cholesterol levels compared with the respective monotherapies (additional 13.3% decrease vs fluvastatin XL and additional 30.4%
Acknowledgment
The most important acknowledgement is to participants in the study and to the doctors, nurses, and administrative staff in centers throughout Europe and the United States who assisted with its conduct. The study authors acknowledge the assistance of Sajda Ghani, BSc, MSc, and Peter J. Diggle, PhD, for statistical support and of Felicity Sellers, DPhil, for collating author comments and initial editorial assistance.
References (20)
- et al.
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial
Mayo Clin Proc
(2004) - et al.
Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
Am J Cardiol
(2003) - et al.
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein
Am J Cardiol
(2003) - et al.
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial
Mayo Clin Proc
(2005) - et al.
Dose-comparison study of the combination of Ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
Am J Heart
(2005) - et al.
Monotherapy with ezetimibe causing myopathy
Am J Med
(2006) - et al.
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
J Am Coll Cardiol
(2002) - et al.
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Circulation
(2003) - et al.
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
Int J Clin Pract
(2004) - et al.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Clin Chem
(1972)
Cited by (99)
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
2022, American Journal of the Medical SciencesStatin Intolerance and Noncompliance: An Empiric Approach
2022, American Journal of MedicineMuscular complications of statins
2021, Medecine des Maladies MetaboliquesPRavastatin Versus FlUVastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching
2019, American Journal of MedicineAtorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells
2017, Biochemical and Biophysical Research CommunicationsOptimizing Cholesterol Treatment in Patients With Muscle Complaints
2017, Journal of the American College of CardiologyCitation Excerpt :Bile acid sequestrants are not absorbed and these agents would not be expected to have adverse muscle complaints even though some patients report SAMS with bile acid sequestrants (50). Studies in patients with statin intolerance have shown that the majority of patients are able to tolerate ezetimibe (50–55). The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) evaluated the effect of ezetimibe combined with simvastatin compared with simvastatin alone in stable patients following acute coronary syndrome (55).
The study was funded by Novartis Pharma AG, Basel, Switzerland.
The Clinical Trials.gov number is NCT00125125.